Heinz Gisslinger

Heinz Gisslinger

Auto-generated profile, based on publicly available information

Heinz Gisslinger

Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The Lancet Haematology
Verified
Journal Article
Closed access
HGHeinz Gisslinger
Heinz Gisslinger
CKChristoph Klade
Christoph Klade
PGPencho Georgiev
Pencho Georgiev
DKDorota Krochmalczyk
Dorota Krochmalczyk
LGLiana Gercheva-Kyuchukova
Liana Gercheva-Kyuchukova
DWDominik Wolf
Dominik Wolf

7 March 2013 in Blood
Verified
Journal Article
Open access
PDF file
HGHeinz Gisslinger
Heinz Gisslinger
MGMirjana Gotic
Mirjana Gotic
JHJerzy Holowiecki
Jerzy Holowiecki
MPMiroslav Penka
Miroslav Penka
JTJuergen Thiele
Juergen Thiele
PPPetro E. Petrides
Petro E. Petrides
Key Points: Noninferiority of anagrelide in comparison with hydroxyurea in WHO-essential thrombocythemia, a phase 3 trial

21 January 2016 in Blood
Verified
Journal Article
Open access
PDF file
JFJelena Milosevic Feenstra
Jelena Milosevic Feenstra
HNHarini Nivarthi
Harini Nivarthi
HGHeinz Gisslinger
Heinz Gisslinger
ELEmilie Leroy
Emilie Leroy
ERElisa Rumi
Elisa Rumi
RKRobert Kralovics
Robert Kralovics
Key Points: Activating mutations outside exon 10 of MPL were identified in 10% (7 of 69) of triple-negative cases of ET and PMF. JAK2-V625F and JAK2-F556V were identified in 2 triple-negative cases of ET and were shown to activate JAK-STAT5 signaling.

8 October 2015 in Blood
Verified
Journal Article
Open access
PDF file
HGHeinz Gisslinger
Heinz Gisslinger
OZOleh Zagrijtschuk
Oleh Zagrijtschuk
VBVeronika Buxhofer-Ausch
Veronika Buxhofer-Ausch
JTJosef Thaler
Josef Thaler
ESErnst Schloegl
Ernst Schloegl
RGRichard Greil
Richard Greil
Key Points: The novel IFNα-2b, ropeginterferon alfa-2b, administered once every 2 weeks has low toxicity and induces high and sustained response rates in polycythemia vera patients. Ropeginterferon alfa-2b induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.

29 January 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
AKAleksandra E. Kornienko
Aleksandra E. Kornienko
CDChristoph P. Dotter
Christoph P. Dotter
PGPhilipp M. Guenzl
Philipp M. Guenzl
HGHeinz Gisslinger
Heinz Gisslinger
BGBettina Gisslinger
Bettina Gisslinger
DBDenise P. Barlow
Denise P. Barlow
Long non-coding RNAs (lncRNAs) are increasingly implicated as gene regulators and may ultimately be more numerous than protein-coding genes in the human genome. Despite large numbers of reported lncRNAs, reference annotations are likely incomplete due to their lower and tighter tissue-specific expression compared to mRNAs. An unexplored factor potentially confounding lncRNA identification is inter-individual expression variability. Here, we characterize lncRNA natural expression variability in human primary granulocytes. We annotate granulocyte lncRNAs and mRNAs in RNA-seq data from 10 healthy individuals, identifying multiple lncRNAs absent from reference annotations, and use this to investigate three known features (higher tissue-specificity, lower expression, and reduced splicing efficiency) of lncRNAs relative to mRNAs. Expression variability was examined in seven individuals sampled three times at 1- or more than 1-month intervals. We show that lncRNAs display significantly more inter-individual expression variability compared to mRNAs. We confirm this finding in two independent human datasets by analyzing multiple tissues from the GTEx project and lymphoblastoid cell lines from the GEUVADIS project. Using the latter dataset we also show that including more human donors into the transcriptome annotation pipeline allows identification of an increasing number of lncRNAs, but minimally affects mRNA gene number. A comprehensive annotation of lncRNAs is known to require an approach that is sensitive to low and tight tissue-specific expression. Here we show that increased inter-individual expression variability is an additional general lncRNA feature to consider when creating a comprehensive annotation of human lncRNAs or proposing their use as prognostic or disease markers.

12 November 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ESEmanuela Sant'ANtonio
Emanuela Sant'ANtonio
PGPaola Guglielmelli
Paola Guglielmelli
LPLisa Pieri
Lisa Pieri
MPMassimo Primignani
Massimo Primignani
Maria Luigia RandiMaria Luigia Randi
Maria Luigia Randi
AVAlessandro Maria Vannucchi
Alessandro Maria Vannucchi